Cyst expansion and regression in a mouse model of polycystic kidney disease

Kidney International

Volumn 83, Issue 6, 2013, Pages 1099-1108

  Happé, Hester ^a   Van Der Wal, Annemieke M ^a   Salvatori, Daniela C F ^a   Leonhard, Wouter N ^a   Breuning, Martijn H ^a   De Heer, Emile ^a   Peters, Dorien J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADPKD; Cystic kidney; Fibrosis; Inflammation; Kidney volume

Indexed keywords

UREA;

129OLA MOUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL INFILTRATION; CONTROLLED STUDY; CYST EXPANSION; CYST REGRESSION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MODEL; FEMALE; GENE; GENE EXPRESSION; HSD MOUSE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; KIDNEY COLLECTING TUBULE; KIDNEY DISTAL TUBULE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY PROXIMAL TUBULE; KIDNEY SIZE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; ORTHOLOGY; PATHOPHYSIOLOGY; PKD1 GENE; PRIORITY JOURNAL; SURVIVAL TIME; TRANSCRIPTION REGULATION; UREA BLOOD LEVEL;

EID: 84882282734     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.13     Document Type: Article

References (48)

1. Gabow PA. Autosomal dominant polycystic kidney disease-more than a renal disease. Am J Kidney Dis 1990; 16: 403-413.
2. Qian F, Watnick TJ, Onuchic LF et al. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996; 87: 979-987.
3. Ong AC, Harris PC. Molecular basis of renal cyst formation-one hit or two? Lancet 1997; 349: 1039-1040.
4. Rossetti S, Kubly VJ, Consugar MB et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 2009; 75: 848-855.
5. Vujic M, Heyer CM, Ars E et al. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol 2010; 21: 1097-1102.
6. Losekoot M, Ruivenkamp CAL, Tholens AP et al. Neonatal onset autosomal dominant polycystic kidney disease (ADPKD) in a patient homozygous for a PKD2 missense mutation due to uniparental disomy. J Med Genet 2012; 49: 37-40.
7. Zeier M, Fehrenbach P, Geberth S et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42: 1259-1265.
8. Okada H, Ban S, Nagao S et al. Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int 2000; 58: 587-597.
9. Martinez JR, Grantham JJ. Polycystic kidney disease: etiology, pathogenesis, and treatment. Dis Mon 1995; 41: 693-765.
10. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 2004; 13: 3069-3077.
11. Hassane S, Claij N, Lantinga-van Leeuwen IS et al. Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model. Arterioscler Thromb Vasc Biol 2007; 27: 2177-2183.
12. Hassane S, Leonhard WN, van der Wal A et al. Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J Pathol 2010; 222: 21-31.
13. The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome. Cell 1994; 77: 881-894.
14. Meijer E, Boertien WE, Nauta FL et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 2010; 56: 883-895.
15. Bolignano D, Coppolino G, Campo S et al. Neutrophil gelatinaseassociated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 2007; 27: 373-378.
16. Bolignano D, Donato V, Coppolino G et al. Neutrophil gelatinaseassociated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52: 595-605.
17. Lai X, Bacallao RL, Blazer-Yost BL et al. Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteomics Clin Appl 2008; 2: 1140-1152.
18. Mrug M, Zhou J, Woo Y et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 2008; 73: 63-76.
19. Boulter C, Mulroy S, Webb S et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 2001; 98: 12174-12179.
20. Kim K, Drummond I, Ibraghimov-Beskrovnaya O et al. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 2000; 97: 1731-1736.
21. Muto S, Aiba A, Saito Y et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002; 11: 1731-1742.
22. Wu G, Markowitz GS, Li L et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 2000; 24: 75-78.
23. Lu W, Shen X, Pavlova A et al. Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum Mol Genet 2001; 10: 2385-2396.
24. Trudel M, Kurbegovic A. Toward understanding Pkd1 cystogenetic mechanism. J Am Soc Nephrol 2011; 22: 59A.
25. Ahrabi AK, Jouret F, Marbaix E et al. Glomerular and proximal tubule cysts as early manifestations of Pkd1 deletion. Nephrol Dial Transplant 2010; 25: 1067-1078.
26. Jiang ST, Chiou YY, Wang E et al. Defining a link with autosomaldominant polycystic kidney disease in mice with congenitally low expression of Pkd1. Am J Pathol 2006; 168: 205-220.
27. Wang E, Hsieh-Li HM, Chiou YY et al. Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1. J Pathol 2010; 222: 238-248.
28. Bourdeau A, Faughnan ME, McDonald ML et al. Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 2001; 158: 2011-2020.
29. King VL, Trivedi DB, Gitlin JM et al. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1137-1143.
30. Geng H, Lan R, Wang G et al. Inhibition of autoregulated TGFbeta signaling simultaneously enhances proliferation and differentiation of kidney epithelium and promotes repair following renal ischemia. Am J Pathol 2009; 174: 1291-1308.
31. Lin F, Hiesberger T, Cordes K et al. Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci USA 2003; 100: 5286-5291.
32. Happé H, Leonhard WN, van der Wal A et al. Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum Mol Genet 2009; 18: 2532-2542.
33. Song X, Di G V, He N et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 2009; 18: 2328-2343.
34. Happé H, van der Wal AM, Leonhard WN et al. Altered Hippo signalling in polycystic kidney disease. J Pathol 2011; 224: 133-142.
35. Karihaloo A, Koraishy F, Huen SC et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22: 1809-1814.
36. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
37. Gunay-Aygun M, Font-Montgomery E, Lukose L et al. Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 972-984.
38. Bergmann C, Senderek J, Windelen E et al. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int 2005; 67: 829-848.
39. Woo D. Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 1995; 333: 18-25.
40. Shibazaki S, Yu Z, Nishio S et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 2008; 17: 1505-1516.
41. Leonhard WN, van der Wal A, Novalic Z et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 2011; 300: F1193-F1202.
42. Caroli A, Antiga L, Conti S et al. Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. Am J Pathol 2011; 179: 619-627.
43. Grantham JJ. Polycystic kidney disease: neoplasia in disguise. Am J Kidney Dis 1990; 15: 110-116.
44. Watnick T, Germino GG. mTOR inhibitors in polycystic kidney disease. N Engl J Med 2010; 363: 879-881.
45. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829.
46. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840.
47. Novalic Z, van der Wal AM, Leonhard WN et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012; 23: 842-853.
48. Christensen EI, Nielsen S, Moestrup SK et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol 1995; 66: 349-364.